What the FDA labels say about taking them together
Atorvastatin and nirmatrelvir/ritonavir
Nirmatrelvir/ritonavir's FDA label of February 19, 2026 names atorvastatin in its drug interactions section; the atorvastatin labels PlainMeds reads (2) do not name nirmatrelvir/ritonavir.
Check it at the source: the atorvastatin FDA label on DailyMed (effective April 15, 2024, Viatris Specialty LLC); the nirmatrelvir/ritonavir FDA label on DailyMed (effective February 19, 2026, Pfizer Laboratories Div Pfizer Inc).
What does the atorvastatin label say about nirmatrelvir/ritonavir?
Atorvastatin's label (effective April 15, 2024) and its 1 other brand-application label do not name nirmatrelvir/ritonavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Lipitor), NDA020702 (Upjohn), as published by Viatris Specialty LLC, effective April 15, 2024 (SPL set a60cc18b-0631-4cf0-b021-9f52224ece65), via openFDA; the full label on DailyMed
What does the nirmatrelvir/ritonavir label say about atorvastatin?
Nirmatrelvir/ritonavir label, drug interactionsDrug Class: HMG-CoA reductase inhibitors; Drugs within Class: atorvastatin; Effect on Concentration: ↑ atorvastatin; Clinical Comments: Consider temporary discontinuation of atorvastatin during treatment with PAXLOVID. Atorvastatin does not need to be withheld prior to or after completing PAXLOVID.
Source: FDA drug label (Paxlovid), Pfizer Laboratories Div Pfizer Inc, effective February 19, 2026 (SPL set 8a99d6d6-fd9e-45bb-b1bf-48c7f761232a), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
These are the ingredient's own label sentences, repeated in a combination product's or a biosimilar's label. The ingredient pair sets them out with both labels side by side.
Both medicines on the record
| Atorvastatin | Nirmatrelvir/ritonavir | |
|---|---|---|
| Labeled for | High cholesterol, Angina, High triglycerides, Heart attack and coronary artery disease | COVID-19 |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0228 per tablet 10 mg tablet | $49.24 per unit 300-100 mg dose pack |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once